The Therapeutic Options For Treating Type 2 Diabetes Mellitus

1054 Words Oct 9th, 2014 5 Pages
The therapeutic options for treating type 2 diabetes mellitus (T2DM) have been widened since April 2005 due to the introduction of Exenatide, the first incretin mimetic (Bond 2006). Due to the prevalence of this disease, the largest and most powerful pharmaceutical companies are ambitious to develop effective therapeutic methods. Exenatide is a synthetic peptide that was first identified in the saliva of Heloderma Suspectum, a species of venomous lizard native to areas in the United States and Mexico (Kalra 2013). In this review, the focus is on the mechanisms of exenatide and how these may relate to therapeutic responses . The exact mechanisms of Exenatide are continually under investigation with certain evaluations focusing on the treatment of conditions including obesity, diabetes and Parkinsons Disease.

Exenatide functions to aid in the control of DM and should be considered with alternative health lifestyles (Derosa, 2010). Additionally, patients that are on insulin supplementation should not incorporate Exenatide treatment into their DM regimen as it is not approved and yet to be studied (Iltz, 2006). Exendin-4 is a natural peptide which bears a 53% homology to the human glucagon-like peptide-1 (GLP-1) (Kalra 2013). GLP-1 is produced in the intestinal epithelial endocrine L-cells and liberated, following post translational processing of a proglucagon precursor that stimulates insulin secretion, as well as reducing the rate of gastric…
Open Document